Objective The risk of hepatitis B virus (HBV) reactivation with non-tumour necrosis factor
inhibitor (non-TNFi) biologic agents in patients with rheumatic diseases and past HBV …

Introduction: Targeted therapies have gained popularity in the treatment of several oncologic
and immune-mediated diseases. Immunosuppression caused by these drugs has been …

Hepatitis B virus (HBV) reactivation under systemic chemotherapy or immunosuppressive
therapy is a serious complication among HBV‐resolved patients. Some medications, such …

Hepatitis B Reactivation in Rheumatic Diseases - Rheumatic Disease Clinics Skip to Main
Content Skip to Main Menu Advertisement Rheumatic Disease Clinics Log in Register Log in …

The aims of this paper are to report hepatitis B virus reactivation in 12 patients with
rheumatic disease undergoing immunosuppressive therapy and to evaluate whether pre …

Background Abatacept is a selective T-cell costimulation modulator approved for the
treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Reports …

Background The role of antiviral prophylaxis before chemotherapy or immunosuppressive
therapy to prevent hepatitis B virus (HBV) reactivation in patients with resolved HBV infection …

Objective Immunosuppressive therapy may trigger hepatitis B virus (HBV) reactivation for
increased morbidity and mortality. We aimed to describe HBV reactivation in patients …

Background & Aims In patients who have resolved hepatitis B virus (HBV) infection,
treatment of rheumatoid arthritis (RA) can result in reappearance of hepatitis B surface …

Background The hepatitis B virus (HBV) is one of the leading causes of acute, chronic and
occult hepatitis (OBI) representing a serious public health threat. Cytokines are known to be …